$31.80
Value $1.8B
ASTH and RTX stock compared: price, dividend, valuation and results, from SEC filings.
$31.80
Value $1.8B
$198.58
Value $266B
Astrana Health (ASTH) has a market value of $1.8B and RTX (RTX) $266B. Over the last year, with dividends, ASTH moved +35.0% and RTX +13.4%. The P/E is 33.3 for ASTH and 31.7 for RTX. Dividend yield: ASTH 0.09%, RTX 1.42%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ASTH$1.8B
RTX$266B
RTX is 151 times ASTH
Revenue, 12 months
ASTH$3.9B
RTX$96.0B
RTX is 25 times ASTH
Net income, 12 months
ASTH$53M
RTX$8.4B
RTX is 158 times ASTH
Operating margin
ASTH3.1%
RTX11.8%
8.7 points apart
ROIC
ASTH4.5%
RTX8.8%
4.3 points apart
P/E
ASTH33.3
RTX31.7
About the same
Dividend yield
ASTH0.1%
RTX1.4%
1.3 points apart
5-year return
ASTH-71.1%
RTX+148.8%
219.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ASTH-71.1%
RTX+148.8%
| Period | ASTHWith dividends | RTXWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +35.0%Price +35.0% | +13.4%Price +11.8% |
| 3 years since November 13, 2023 | +1.4%+0.5% a yearPrice +1.4% | +157.0%+37.0% a yearPrice +142.1% |
| 5 years since November 12, 2021 | -71.1%-22.0% a yearPrice -71.1% | +148.8%+20.0% a yearPrice +123.5% |
| 10 years since November 15, 2016 | +606.7%+21.6% a yearPrice +606.7% | +268.0%+13.9% a yearPrice +193.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ASTHAstrana HealthRTXRTX
| Price | $31.80 | $198.58 |
|---|---|---|
| Market value | $1.8B | $266B |
| Enterprise value (EV) | $2.3B | $294B |
| P/E | 33.3 | 31.7 |
| P/E, 5-year median | 35.0 | 33.6 |
| P/B | 2.1 | 3.9 |
| EV/EBIT | 19.0 | 26.0 |
| Free cash flow yield | 5.6% | 3.6% |
| Revenue, 12 months | $3.9B | $96.0B |
|---|---|---|
| Net income, 12 months | $53M | $8.4B |
| Free cash flow, 12 months | $99M | $9.5B |
| Earnings per share, 12 months | $0.96 | $6.16 |
| Revenue growth, year on year | 56.4% | 9.7% |
| Revenue growth a year, past | +35.9%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | -14.5%over 5 years | – |
| Gross margin | 11.0% | – |
|---|---|---|
| Operating margin | 3.1% | 11.8% |
| Net margin | 1.4% | 8.8% |
| ROIC | 4.5% | 8.8% |
| ROE | 6.6% | 12.7% |
| Cash | $396M | $9.9B |
|---|---|---|
| Total debt | $977M | $38.9B |
| Net debt / EBITDA | 3.2 | 1.8 |
| Interest cover | 1.9× | – |
| Dividend yield | 0.1% | 1.4% |
|---|---|---|
| Dividend per share, 12 months | $0.03 | $2.82 |
| Dividend growth a year, past | – | +4.3%over 5 years |
| Buyback yield | 1.5% | 0.0% |
| Shareholder yield | 1.5% | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, RTX ($266B) is about 150.6 times Astrana Health ($1.8B), at today's prices.
Since November 15, 2016, ASTH's price moved +606.7% and RTX's +193.0%. With dividends: ASTH +606.7% (+21.6% a year), RTX +268.0% (+13.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.09% for Astrana Health and 1.42% for RTX. Over the last twelve months they paid $0.03 and $2.82 per share.
At today's price, the P/E is 33.3 for ASTH and 31.7 for RTX. The median of the last five years was 35.0 and 33.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 1.4% for Astrana Health and 8.8% for RTX, and the operating margin 3.1% and 11.8%. Revenue was $3.9B and $96.0B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.